Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cefonicid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.77 |
| ▸ | SLC22A8 | Q8TCC7 | 2/20 | 0.77 |
| ▸ | SLC22A11 | Q9NSA0 | 2/20 | 0.77 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.77 |
| ▸ | PGR | P06401 | 1/20 | 0.77 |
| ▸ | PPARG | P37231 | 1/20 | 0.77 |
| ▸ | TDP1 | Q9NUW8 | 10/20 | 0.68 |
| ▸ | MAPT | P10636 | 9/20 | 0.68 |
| ▸ | POLB | P06746 | 9/20 | 0.68 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.68 |
| ▸ | HPGD | P15428 | 1/20 | 0.68 |
| ▸ | APEX1 | P27695 | 1/20 | 0.68 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cefonicid SCHEMBL13297839 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC22A6SLC22A8SLC22A11NR1I2 | |
| Cefonicid SCHEMBL16072827 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC22A6SLC22A8SLC22A11NR1I2 | |
| Cefonicid SCHEMBL60350 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC22A6SLC22A8SLC22A11NR1I2 | |
| Cefonicid SCHEMBL9080022 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC22A6SLC22A8SLC22A11NR1I2 | |
| Cefonicid SCHEMBL18048103 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC22A6SLC22A8SLC22A11NR1I2 | |
| Cefonicid SCHEMBL28744041 | 0.99 | SLC6A4 (0.99) | SLC6A4SLC22A6SLC22A8SLC22A11NR1I2 | |
| Cefonicid SCHEMBL27856008 | 0.99 | SLC6A4 (0.99) | SLC6A4SLC22A6SLC22A8SLC22A11NR1I2 | |
| Cefonicid SCHEMBL41894 | 0.99 | SLC6A4 (0.99) | SLC6A4SLC22A6SLC22A8SLC22A11NR1I2 | |
| Cefonicid SCHEMBL27865839 | 0.99 | SLC6A4 (0.99) | SLC6A4SLC22A6SLC22A8SLC22A11NR1I2 | |
| Cefonicid SCHEMBL8425120 | 0.99 | SLC6A4 (0.99) | SLC6A4SLC22A6SLC22A8SLC22A11NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 162 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9227999-B2 | Antimicrobial cationic peptides and formulations thereof | CARRUS CAPITAL CORPORATION (CA) | 2016-01-05 | — | — | US | claimed |
| EP-3866826-B1 | ANTIMICROBIAL PEPTIDES AND METHODS OF USING THE SAME | RIPTIDE BIOSCIENCE INC (US) | 2025-12-10 | — | — | EP | disclosed |
| US-20240082228-A1 | SARS-COV-2 THERAPEUTICS | MODEL MEDICINES INC (US) | 2024-03-14 | — | — | US | disclosed |
| US-11266712-B2 | Antimicrobial peptides and methods of using the same | Riptide Bioscience, Inc. (US) | 2022-03-08 | — | — | US | disclosed |
| CN-113226349-A | Antimicrobial peptides and methods of use thereof | 激流生物科学有限公司 | 2021-08-06 | — | — | CN | disclosed |
| US-20210087565-A1 | ANTISENSE ANTIBIOTICS AND BACTERIAL SECRETION BASED DELIVERY SYSTEM TO ELIMINATE DRUG-RESISTANT BACTERIA | NATIONAL SCIENCE FOUNDATION | 2021-03-25 | — | — | US | disclosed |
| US-10913790-B2 | Compositions of, and methods for, alpha-1 anti trypsin Fc fusion molecules | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2021-02-09 | — | — | US | disclosed |
| US-20200385715-A1 | COMPOSITIONS AND METHODS FOR ALTERING BACTERIA FITNESS | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2020-12-10 | — | — | US | disclosed |
| US-10842811-B2 | Inulin for preventing antibiotic resistant infection and pathogen colonization | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2020-11-24 | — | — | US | disclosed |
| US-20200230200-A1 | Antimicrobial Peptides and Methods of Using the Same | UNITED STATES GOVERNMENT | 2020-07-23 | — | — | US | disclosed |
| EP-0925308-B1 | COMPOSITIONS AND METHODS FOR TREATING INFECTIONS USING ANALOGUES OF INDOLICIDIN | MICROLOGIX BIOTECH INC (CA) | 2002-06-05 | — | — | EP | disclosed |
| US-20020035061-A1 | COMPOSITIONS AND METHODS FOR TREATING INFECTIONS USING CATIONIC PEPTIDES ALONE OR IN COMBINATION WITH ANTIBIOTICS | BIOWEST THERAPEUTICS INC. (CA) | 2002-03-21 | — | — | US | disclosed |
| EP-1174439-A2 | Compositions and methods for treating infections using analogues of indolicidin | Micrologix Biotech, Inc. (CA) | 2002-01-23 | — | — | EP | disclosed |
| US-6180604-B1 | Compositions and methods for treating infections using analogues of indolicidin | MICROLOGIX BIOTECH INC. (CA) | 2001-01-30 | — | — | US | disclosed |
| EP-0966481-A2 | COMPOSITIONS AND METHODS FOR TREATING INFECTIONS USING CATIONIC PEPTIDES ALONE OR IN COMBINATION WITH ANTIBIOTICS | Micrologix Biotech, Inc. (CA) | 1999-12-29 | — | — | EP | disclosed |
| WO-1999065506-A2 | CANCER THERAPY WITH INDOLICIDIN OR CATIONIC PEPTIDES AND THEIR POLYMER CONJUGATES | MICROLOGIX BIOTECH INC. (CA) | 1999-12-23 | — | — | WO | disclosed |
| EP-0925308-A2 | COMPOSITIONS AND METHODS FOR TREATING INFECTIONS USING ANALOGUES OF INDOLICIDIN | Micrologix Biotech, Inc. (CA) | 1999-06-30 | — | — | EP | disclosed |
| WO-1998040401-A2 | COMPOSITIONS AND METHODS FOR TREATING INFECTIONS USING CATIONIC PEPTIDES ALONE OR IN COMBINATION WITH ANTIBIOTICS | MICROLOGIX BIOTECH INC. (CA) | 1998-09-17 | — | — | WO | disclosed |
| WO-1998007745-A9 | COMPOSITIONS AND METHODS FOR TREATING INFECTIONS USING ANALOGUES OF INDOLICIDIN | — | 1998-04-23 | — | — | WO | disclosed |
| WO-1998007745-A2 | COMPOSITIONS AND METHODS FOR TREATING INFECTIONS USING ANALOGUES OF INDOLICIDIN | MICROLOGIX BIOTECH, INC. (CA) | 1998-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035061-A1 | COMPOSITIONS AND METHODS FOR TREATING INFECTIONS USING CATIONIC PEPTIDES ALONE OR IN COMBINATION WITH ANTIBIOTICS | VIP, PEPD, PTMS | SLC6A4 4137/4885SLC22A6 3082/4885SLC22A8 1539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.